

## OUR SERVICES

### Nano ChIP-Seq Service: Addressing Unmet Needs in Epigenomic Biomarker Discovery

The **Nano ChIP-Seq** technology unlocks the opportunities of investigating post-translational modification of histone in tissue biopsies. It requires 20x less material as compared standard ChIP kits. This ultra sensitive technology enables a wider-range of applications for discovering, validating, and screening genome-wide histone modification in a reliable and efficient manner.

### High Quality ChIP-seq Data with Low Sample Input and High Sensitivity




Fig 1. A snapshot of genome tracks showing regions with histone modification (peaks) using Signomax Nano ChIP-Seq technology that generated similar results as standard protocol with much lesser cells.




Fig 2. Performance output of Signomax vs other Commercial ChIP-Seq Vendors

## Key Features

- Up to 2x more sensitivity than standard ChIP methods
- Low sample input: 1 - 2 Million cells
- Optimized for *in vitro* and *in vivo* samples
- Compatible with leading Next-Gen sequencing platforms

## Technical Specifications

- Histone modifications marks: H3K4me3 and/or H3K27ac
- Sample types: FFPE, Fresh Frozen Tissue, and Cell Lines
- ISO9001 certified workflow, high reproducibility

### Key Publications

1. Muratani et al., 2014 *Nature Communications*
2. Ooi et al., 2016 *Nature Communications*
3. Qamra et al., 2017 *Cancer Discovery*
4. Yao et al., 2017 *Cancer Discovery*
5. Xing et al., 2020 *The Journal of Clinical Investigation*

### ABOUT US

Auristone is an Asian-based epigenomic profiling company with data analytics capabilities and is dedicated to developing innovative research solutions to accelerate epigenomic clinical research.

**AURISTONE PTE. LTD.**  
73 Ayer Rajah Crescent #02-19  
S(139952)

[www.auristone.com](http://www.auristone.com)  
[enquiry@auristone.com](mailto:enquiry@auristone.com)